Business Context and Reporting Period
This Form 8-K filing by Pavmed Inc. (PAVM) covers events occurring on June 10, 2021, with the report dated June 14, 2021. The company is an emerging growth company incorporated in Delaware, with principal executive offices in New York. The filing primarily addresses changes to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes rather than financial performance data.
Material Changes
- Board Appointment: Tim Baxter was appointed as a Class A director on June 10, 2021. He will join the audit and nominating committees.
- Board Resignation: David S. Battleman, M.D., resigned from the board of directors on June 10, 2021.
- Reason for Resignation: Dr. Battleman's resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
Management Commentary and Risks
Management highlighted Mr. Baxter's extensive background, including thirteen years in senior executive roles at Samsung Electronics and ten years at Sony Corporation, as well as prior experience at AT&T and Lucent Technologies. The Company expects to enter into a standard indemnification agreement with Mr. Baxter. No unusual items, contingencies, or specific financial risks were disclosed in this filing.
Investor Verification Checklist
- Verify the press release issued on June 14, 2021, for additional details on the board composition.
- Confirm the effective date of Mr. Baxter's committee assignments (Audit and Nominating).
- Review subsequent filings for the execution of the standard indemnification agreement with Mr. Baxter.
- Check for any related party transactions involving the new director, though none were reported in this filing.